Breaking News Instant updates and real-time market news.

CYTK

Cytokinetics

$8.17

0.06 (0.74%)

, AMGN

Amgen

$220.84

2.29 (1.05%)

09:11
11/18/19
11/18
09:11
11/18/19
09:11

Cytokinetics, Amgen, Servier announce results from COSMIC-HF Phase 2 trial

Amgen (AMGN), Cytokinetics (CYTK) and Servier announced that new results from COSMIC-HF, a Phase 2 trial evaluating omecamtiv mecarbil in patients with heart failure with reduced ejection fraction, will be presented today at the American Heart Association's Scientific Sessions 2019 in Philadelphia. In patients with HFrEF treated with omecamtiv mecarbil, in addition to previously reported improvements in cardiac contractility measures, measures of diastolic function were not different from placebo and, for some measures, trended towards improvement. In COSMIC-HF, 448 patients with stable, symptomatic heart failure and left ventricular ejection fraction less than40% were randomly assigned to omecamtiv mecarbil or placebo in a double-blind fashion for 20 weeks. This post-hoc analysis assessed the effect of chronic therapy with omecamtiv mecarbil by treatment group on echocardiographic measures of diastolic function, including early and late peak mitral inflow velocities, early peak myocardial relaxation velocity, isovolumic relaxation time, tricuspid regurgitation velocity and diastolic filling time. In patients with HFrEF who received omecamtiv mecarbil, systolic ejection time increased as previously reported and expected, while diastolic filling time was not reduced, nor were diastolic parameters worsened. Specifically, in patients receiving omecamtiv mecarbil E-wave velocity, E/A-ratio, and E/e' or e' were not significantly changed compared to placebo. There was a small increase in the duration of the IVRT, and in the PK group, TRV, an indicator of pulmonary pressure, improved significantly during treatment with omecamtiv mecarbil therapy

CYTK

Cytokinetics

$8.17

0.06 (0.74%)

AMGN

Amgen

$220.84

2.29 (1.05%)

  • 07

    Dec

CYTK Cytokinetics
$8.17

0.06 (0.74%)

09/06/19
CANT
09/06/19
NO CHANGE
Target $20
CANT
Overweight
Cytokinetics price target raised to $20 from $14 at Cantor Fitzgerald
Cantor Fitzgerald analyst Charles Duncan raised his price target for Cytokinetics to $20 from $14 and reiterates an Overweight rating on the shares ahead of the annual Heart Failure Society of America meeting, which starts September 13. The analyst expects top-line Phase 1 CK-274 results in healthy volunteers. Cytokinetics first premiered CK-274, a cardiac sarcomere inhibitor, for the treatment of hypertrophic cardiomyopathy last October, and management has expressed a high level of confidence in the therapeutic candidate's best-in-class potential, Duncan tells investors in a research note.
09/13/19
JMPS
09/13/19
NO CHANGE
Target $23
JMPS
Outperform
Cytokinetics price target raised to $23 from $15 at JMP Securities
JMP Securities analyst Jason Butler raised his price target on Cytokinetics to $23 and kept his Buy rating, saying the company's upcoming presentation of its CK-274 phase 1 study results at the 2019 HFSA Scientific Meeting this weekend offer an "an opportunity to confirm differentiated pharmacology and highlight the agent's value proposition". The analyst adds that he is specifically looking to confirm a shorter half live in the trial relative to mavacamten's 7-day period.
09/16/19
PIPR
09/16/19
NO CHANGE
Target $20
PIPR
Overweight
Cytokinetics price target raised to $20 from $14 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff raised his price target for Cytokinetics (CYTK) to $20 from $14 after the company presented Phase I data on its wholly-owned cardiac myosin inhibitor CK-274 for hypertrophic cardiomyopathy at this weekend's Heart Failure Society of America meeting. CK-274 was safe and well-tolerated in doses up to 75mg in 81 healthy adults with no observed serious adverse events, Tenthoff tells investors in a research note. CK-274 has a similar mechanism of action to MyoKardia's (MYOK) mavacamten and this weekend's Phase I data "largely de-risk" CK-274, says Tenthoff. He reiterates an Overweight rating on Cytokinetics.
11/01/19
NEED
11/01/19
NO CHANGE
Target $24
NEED
Buy
Cytokinetics price target raised to $24 from $16 at Needham
Needham analyst Chad Messer raised his price target on Cytokinetics to $24 and kept his Buy rating, saying he is including CK-274 in his valuation after its phase 1 results presented last month. The analyst notes that he continues to view omecamtiv as the "backbone" in valuation model given the "enormous unmet need in heart failure."
AMGN Amgen
$220.84

2.29 (1.05%)

11/05/19
11/05/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Facebook (FB) upgraded to Buy from Outperform at Daiwa with analyst Satoshi Tanaka saying the company's Q3 results and 2020 outlook last week go a "long way to alleviate concerns." 2. Beyond Meat (BYND) upgraded to Outperform from Market Perform at Bernstein with analyst Alexia Howard saying she is making a "straightforward valuation call" with the shares down 66% from their peak. 3. NXP Semiconductors (NXPI) upgraded to Buy from Neutral at Mizuho with analyst Vijay Rakesh saying the company's auto segment is showing signs of recovery, with easier compares and content wins. 4. Amgen (AMGN) upgraded to Overweight from Neutral at Cantor Fitzgerald with analyst Alethia Young saying recent events have set the stage for a "clean base business and pipeline story" for Amgen in 2020. 5. Autoliv (ALV) upgraded to Buy from Neutral at Mizuho with analyst Vijay Rakesh saying an improving 2020-2021 auto outlook with easier compares, continued airbag market share gains versus Takata, and lower product launch costs position Autoliv well. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/12/19
RHCO
11/12/19
INITIATION
Target $256
RHCO
Buy
Amgen initiated with a Buy at SunTrust
SunTrust analyst Robyn Karnauskas initiated coverage of Amgen with a Buy rating and $256 price target. The analyst expects the company's growth rate to recover thanks to its biosimilars business, its ability to develop mid-cycle products, and its interest in the Chinese drug market.
11/12/19
11/12/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Arlo Technologies (ARLO) resumed with a Buy at Deutsche Bank. 2. Clarivate Analytics (CCC) initiated with a Hold at Stifel. 3. Stoke Therapeutics (STOK) initiated with a Buy at BTIG. 4. BioMarin (BMRN), Biogen (BIIB), and Amgen (AMGN) were initiated with a Buy at SunTrust. 5. Corteva (CTVA) initiated with a Buy at Redburn. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
11/13/19
COWN
11/13/19
NO CHANGE
Target $225
COWN
Outperform
BeiGene price target raised to $225 from $170 at Cowen
Cowen analyst Yaron Werber raised his price target on BeiGene (BGNE) to $225 from $170 following Q3 results. the report was light due to supply issues for Abraxane, which should reverse in Q4. The analyst said the recent deal with Amgen (AMGN) removes any financing needs, provides a steady pipeline, and provides for 3 new launches in China in 2020 and 2021. Werber reiterated his Outperform rating on BeiGene shares.

TODAY'S FREE FLY STORIES

NWE

NorthWestern

$71.86

0.11 (0.15%)

14:32
12/05/19
12/05
14:32
12/05/19
14:32
Hot Stocks
NorthWestern has new coal supply agreement for Colstrip »

NorthWestern Energy has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SSREY

Swiss Re

$0.00

(0.00%)

, PNXGF

Phoenix Group

$0.00

(0.00%)

14:31
12/05/19
12/05
14:31
12/05/19
14:31
Periodicals
Breaking Periodicals news story on Swiss Re, Phoenix Group »

Phoenix Group in talks to…

SSREY

Swiss Re

$0.00

(0.00%)

PNXGF

Phoenix Group

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

14:17
12/05/19
12/05
14:17
12/05/19
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

14:16
12/05/19
12/05
14:16
12/05/19
14:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLNX

Xilinx

$90.26

0.095 (0.11%)

, ADI

Analog Devices

$113.87

-0.03 (-0.03%)

14:13
12/05/19
12/05
14:13
12/05/19
14:13
Hot Stocks
Xilinx says will 'vigorously defend' self against Analog Devices patent suit »

Xilinx, Inc. (XLNX)…

XLNX

Xilinx

$90.26

0.095 (0.11%)

ADI

Analog Devices

$113.87

-0.03 (-0.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Jan

  • 28

    Jan

PYPL

PayPal

$104.52

-0.46 (-0.44%)

14:07
12/05/19
12/05
14:07
12/05/19
14:07
Periodicals
Breaking Periodicals news story on PayPal »

Hedgeye names PayPal a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 11

    Dec

ALXN

Alexion

$107.06

-8.43 (-7.30%)

, REGN

Regeneron

$369.33

-0.67 (-0.18%)

14:03
12/05/19
12/05
14:03
12/05/19
14:03
Recommendations
Alexion, Regeneron analyst commentary  »

Piper Jaffray a buyer of…

ALXN

Alexion

$107.06

-8.43 (-7.30%)

REGN

Regeneron

$369.33

-0.67 (-0.18%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 16

    Dec

CCEP

Coca-Cola European Partners

$50.07

-0.75 (-1.48%)

13:57
12/05/19
12/05
13:57
12/05/19
13:57
Periodicals
Einride to launch electric pod pilot with Coca-Cola European Partners, TC says »

Darrell Etherington of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOOG

Alphabet

$1,320.51

-0.95 (-0.07%)

13:37
12/05/19
12/05
13:37
12/05/19
13:37
Periodicals
Spain moving forward with 'Google tax' despite U.S. disappointment, El Pais says »

Spain is moving forward…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

WEC

WEC Energy

$89.00

-0.07 (-0.08%)

13:32
12/05/19
12/05
13:32
12/05/19
13:32
Earnings
Breaking Earnings news story on WEC Energy »

WEC Energy sees FY20 EPS…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WEC

WEC Energy

$88.97

-0.1 (-0.11%)

13:31
12/05/19
12/05
13:31
12/05/19
13:31
Hot Stocks
WEC Energy plans to raise quarterly dividend to 63.25c per share »

The board of directors of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TECK

Teck Resources

$15.77

-0.05 (-0.32%)

13:31
12/05/19
12/05
13:31
12/05/19
13:31
Hot Stocks
Teck announces new collective agreement at Carmen de Andacollo operations »

Teck Resourcesannounced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

BIIB

Biogen

$298.44

9.09 (3.14%)

13:28
12/05/19
12/05
13:28
12/05/19
13:28
Recommendations
Biogen analyst commentary  »

Biogen doctor panel…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 05

    Dec

  • 05

    Dec

AAPL

Apple

$264.33

2.55 (0.97%)

13:28
12/05/19
12/05
13:28
12/05/19
13:28
Periodicals
Noted Apple analyst Kuo sees 2021 iPhone without lightning port, 9To5 Mac says »

Apple analyst Ming-Chi…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:25
12/05/19
12/05
13:25
12/05/19
13:25
General news
Treasury Action: the markets have gone into a holding pattern »

Treasury Action: the…

13:25
12/05/19
12/05
13:25
12/05/19
13:25
Conference/Events
BTIG healthcare/biotech analysts to hold an analyst/industry conference call »

Analysts discuss the…

13:25
12/05/19
12/05
13:25
12/05/19
13:25
Conference/Events
Wolfe Research tech strategist to hold analyst/industry webcast »

Tech Strategist…

13:25
12/05/19
12/05
13:25
12/05/19
13:25
Conference/Events
House Financial Services Committee to hold a hearing »

The Subcommittee on…

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

13:17
12/05/19
12/05
13:17
12/05/19
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$346.35

-2.54 (-0.73%)

13:17
12/05/19
12/05
13:17
12/05/19
13:17
Periodicals
Boeing to SEC: Doesn't see 737 MAX cancellations impacting revenue, Reuters says »

In a letter to the SEC…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

13:16
12/05/19
12/05
13:16
12/05/19
13:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$311.24

-0.23 (-0.07%)

, SPX

S&P 500

$0.00

(0.00%)

13:12
12/05/19
12/05
13:12
12/05/19
13:12
General news
Mnuchin says U.S and China trade talks 'on track' after Thursday call »

U.S. Treasury Secretary…

SPY

SPDR S&P 500 ETF Trust

$311.24

-0.23 (-0.07%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PRSC

Providence Service

$57.58

-0.39 (-0.67%)

13:06
12/05/19
12/05
13:06
12/05/19
13:06
Hot Stocks
LogistiCare to provide NEMT brokerage services to certain CCO members »

PacificSource Community…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BIIB

Biogen

$298.02

8.67 (3.00%)

13:06
12/05/19
12/05
13:06
12/05/19
13:06
Recommendations
Biogen analyst commentary  »

Stifel still sees lower…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 05

    Dec

  • 05

    Dec

SAGE

Sage Therapeutics

$62.50

-86.72 (-58.12%)

12:55
12/05/19
12/05
12:55
12/05/19
12:55
Downgrade
Sage Therapeutics rating change  »

Sage Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.